A review of augmentation therapy for alpha-1 antitrypsin deficiency (Q34268108)

1 August 2017

A review of augmentation therapy for alpha-1 antitrypsin deficiency (English)

1 reference

alpha-1-antitrypsin deficiency

1 August 2017

1 reference

Manish Mohanka

1

1 reference

1 August 2017

Danai Khemasuwan

series ordinal

2

1 reference

1 August 2017

James K Stoller

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

14 April 2012

1 reference

Expert Opinion on Biological Therapy

1 August 2017

1 reference

1 August 2017

12

1 reference

1 August 2017

685-700

1 reference

1 August 2017

6

1 reference

Alpha1-antitrypsin deficiency

1 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Clinical practice. Alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

A review of α1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

The role of augmentation therapy in alpha-1 antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Results of a survey of patients with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Alpha1-antitrypsin protects beta-cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Antibody response to aerosolized transgenic human alpha1-antitrypsin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Gene therapy for alpha-1 antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.676638

10.1517/14712598.2012.676638

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference